BioCentury
ARTICLE | Company News

Biogen, Genentech, Chugai, Nippon Shinyaku, Roche sales and marketing update

June 15, 2015 7:00 AM UTC

The U.K.’s NICE issued final guidance recommending Gazyvaro obinutuzumab from Roche in combination with chlorambucil as first-line therapy for chronic lymphocytic leukemia (CLL) in patients who have comorbidities making them unsuitable for full-dose fludarabine-based therapy. The recommendation is only if bendamustine-based therapy is not suitable and Roche provides the drug at an undisclosed discount under a patient access scheme. The decision is in line with the final appraisal determination (FAD) issued in March (see BioCentury, March 23). ...